LINFOMAS Y TRASPLANTES
Claude Bernard University Lyon 1
Villeurbanne, FranciaPublicaciones en colaboración con investigadores/as de Claude Bernard University Lyon 1 (13)
2023
-
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
American Journal of Hematology, Vol. 98, Núm. 11, pp. 1699-1710
2022
-
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 242-251
-
Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Journal of Clinical Oncology
2021
-
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma
European Journal of Cancer, Vol. 157, pp. 132-139
2019
-
Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma
Journal of Clinical Oncology
2018
-
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204
-
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
The Lancet Haematology, Vol. 5, Núm. 8, pp. e359-e367
2017
-
Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2473-2481
2016
-
Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial
Journal of Clinical Oncology, Vol. 34, Núm. 22, pp. 2575-2582
2014
-
Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma
Blood
-
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma
Cancer Treatment Reviews, Vol. 40, Núm. 9, pp. 1080-1088
2013
-
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
Haematologica, Vol. 98, Núm. 3, pp. 357-363